Digest Network Come funziona
Network
/
Società
Im
Non verificato

ImmunityBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

68 comunicati stampa

Guarda tutti i comunicati
07/05/2026
Mercato azionario
Biotecnologia
Salute
Sanità
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Eventi
Fiere
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
21/04/2026
Mercato del lavoro
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
09/04/2026
Mercato azionario
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
06/04/2026
Oncologia
Advertising
Salute
Comunicazione
Igiene alimentare
Farmaceutica
Biotecnologia
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
31/03/2026
Industria
Biotecnologia
Farmaceutica
Salute
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
26/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
20/03/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
17/03/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
13/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0